Literature DB >> 23744588

Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists.

Agostino Cilibrizzi1, Letizia Crocetti, Maria Paola Giovannoni, Alessia Graziano, Claudia Vergelli, Gianluca Bartolucci, Giacomo Soldani, Mark T Quinn, Igor A Schepetkin, Cristina Faggi.   

Abstract

The synthesis of three racemates and the corresponding non-chiral analogues of a C5-methyl pyridazine series is described here, as well as the isolation of pure enantiomers and their absolute configuration assignment. In order to obtain optically active compounds, direct chromatographic methods of separation by HPLC-UV were investigated using four chiral stationary phases (CSPs: Lux Amylose-2, Lux Cellulose-1, Lux Cellulose-2 and Lux Cellulose-3). The best resolution was achieved using amylose tris(5-chloro-2-methylphenylcarbamate) (Lux Amylose-2), and single enantiomers were isolated on a semipreparative scale with high enantiomeric excess, suitable for biological assays. The absolute configuration of optically active compounds was unequivocally established by X-ray crystallographic analysis and comparative chiral HPLC-UV profile. All compounds of the series were tested for formyl peptide receptor (FPR) agonist activity, and four were found to be active, with EC50 values in the micromolar range.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  FPRs; Lux Amylose; Lux Cellulose; absolute configuration; chiral stationary phase; inflammation; liquid chromatography; pyridazinones

Mesh:

Substances:

Year:  2013        PMID: 23744588      PMCID: PMC4299864          DOI: 10.1002/chir.22162

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  20 in total

Review 1.  Inflammatory resolution: new opportunities for drug discovery.

Authors:  Derek W Gilroy; Toby Lawrence; Mauro Perretti; Adriano G Rossi
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.

Authors:  Wenhui Hu; Hantamalala Ralay Ranaivo; Saktimayee M Roy; Heather A Behanna; Laura K Wing; Lenka Munoz; Ling Guo; Linda J Van Eldik; D Martin Watterson
Journal:  Bioorg Med Chem Lett       Date:  2006-10-17       Impact factor: 2.823

3.  The use of X-ray crystallography to determine absolute configuration.

Authors:  H D Flack; G Bernardinelli
Journal:  Chirality       Date:  2008-05-15       Impact factor: 2.437

4.  The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.

Authors:  I Lues; N Beier; R Jonas; M Klockow; G Haeusler
Journal:  J Cardiovasc Pharmacol       Date:  1993-06       Impact factor: 3.105

5.  Functional high efficiency expression of cloned leukocyte chemoattractant receptor cDNAs.

Authors:  J R Didsbury; R J Uhing; E Tomhave; C Gerard; N Gerard; R Snyderman
Journal:  FEBS Lett       Date:  1992-02-10       Impact factor: 4.124

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

7.  New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation.

Authors:  Mike Frohn; Han Xu; Xiaoming Zou; Catherine Chang; Michele McElvaine; Matthew H Plant; Min Wong; Philip Tagari; Randall Hungate; Roland W Bürli
Journal:  Bioorg Med Chem Lett       Date:  2007-09-15       Impact factor: 2.823

8.  6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.

Authors:  Agostino Cilibrizzi; Mark T Quinn; Liliya N Kirpotina; Igor A Schepetkin; Jeff Holderness; Richard D Ye; Marie-Josephe Rabiet; Claudio Biancalani; Nicoletta Cesari; Alessia Graziano; Claudia Vergelli; Stefano Pieretti; Vittorio Dal Piaz; Maria Paola Giovannoni
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

9.  Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils.

Authors:  C N Serhan; J F Maddox; N A Petasis; I Akritopoulou-Zanze; A Papayianni; H R Brady; S P Colgan; J L Madara
Journal:  Biochemistry       Date:  1995-11-07       Impact factor: 3.162

Review 10.  Resolution of inflammation: state of the art, definitions and terms.

Authors:  Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Journal:  FASEB J       Date:  2007-02       Impact factor: 5.191

View more
  7 in total

Review 1.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

2.  Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Richard D Ye; Mark T Quinn
Journal:  Drug Dev Res       Date:  2016-11-18       Impact factor: 4.360

3.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

4.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

5.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

6.  Pyridinone Derivatives as Interesting Formyl Peptide Receptor (FPR) Agonists for the Treatment of Rheumatoid Arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Maria Paola Giovannoni; Liliya N Kirpotina; Andrei I Khlebnikov; Carla Ghelardini; Lorenzo Di Cesare Mannelli; Elena Lucarini; Igor A Schepetkin; Mark T Quinn
Journal:  Molecules       Date:  2021-10-30       Impact factor: 4.411

7.  Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Andrei I Khlebnikov; Letizia Crocetti; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Agostino Cilibrizzi; Mark T Quinn; Patrizia Rossi; Paola Paoli; Maria Paola Giovannoni
Journal:  Chem Biol Drug Des       Date:  2021-07-01       Impact factor: 2.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.